A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
The purpose of this study is to perform a relative bioavailability study between two
 formulations of sildenafil citrate.
Bio-equivalence between two formulations of sildenafil citrate
Inclusion Criteria:

 -  Body mass index higher or equal to 18,5 and lower or equal than 29,9 kg/m2.

 -  Good health conditions or without significant disease, at medical discretion,
 according to the rules defined in the Protocol, and evaluations undergone: clinical
 history, pulse and blood pressure measurements, physical and psychological
 examination, ECG and complementary laboratory examination.

 -  Able to understand the study nature and objective, including the risks and adverse
 effects and willing to cooperate with the investigator and act according to all the
 trial requirements, which is confirmed by signing the Informed Consent Form.

 Exclusion Criteria:

 -  Hypersensitivity to the study drug or to the chemically related compounds; history of
 serious adverse reactions or hypersensitivity to any drug.

 -  History or presence of hepatic or gastrointestinal diseases, or other condition that
 affects the drug absorption, distribution, excretion or metabolism

 -  History of hepatic, renal, lung, gastrointestinal, epileptic, hematological or
 psychiatric disease; hypo or hypertension of whatever etiology which demands treatment
 with drugs; history or occurrence of myocardial infarction, angina and/or cardiac
 failure;